4.7 Article

Shape Abnormalities of Subcortical and Ventricular Structures in Mild Cognitive Impairment and Alzheimer's Disease: Detecting, Quantifying, and Predicting

期刊

HUMAN BRAIN MAPPING
卷 35, 期 8, 页码 3701-3725

出版社

WILEY
DOI: 10.1002/hbm.22431

关键词

Alzheimer's disease; mild cognitive impairment; subcortical structures; lateral ventricles; high field; subsegmentations; shape abnormality; large deformation diffeomorphic metric mapping

资金

  1. NIH [R01 EB000975, NIH P41 RR15241, R01 EB008171, P30 AG010129, K01 AG030514]
  2. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. Abbott
  6. Alzheimer's Association
  7. Alzheimer's Drug Discovery Foundation
  8. Amorfix Life Sciences Ltd.
  9. AstraZeneca
  10. Bayer HealthCare
  11. BioClinica, Inc.
  12. Biogen Idec Inc.
  13. Bristol-Myers Squibb Company
  14. Eisai Inc.
  15. Elan Pharmaceuticals Inc.
  16. Eli Lilly and Company
  17. F. Hoffmann-La Roche Ltd.
  18. affiliated company Genentech, Inc.
  19. GE Healthcare
  20. Innogenetics
  21. N.V.
  22. IXICO Ltd.
  23. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  24. Johnson & Johnson Pharmaceutical Research & Development LLC.
  25. Medpace, Inc.
  26. Merck Co., Inc.
  27. Meso Scale Diagnostics, LLC.
  28. Novartis Pharmaceuticals Corporation
  29. Pfizer Inc.
  30. Servier
  31. Synarc Inc.
  32. Takeda Pharmaceutical Company
  33. Canadian Institutes of Health Research
  34. Foundation for the National Institutes of Health
  35. Northern California Institute for Research and Education
  36. Alzheimer's Disease Cooperative Study at the University of California, San Diego

向作者/读者索取更多资源

This article assesses the feasibility of using shape information to detect and quantify the subcortical and ventricular structural changes in mild cognitive impairment (MCI) and Alzheimer's disease (AD) patients. We first demonstrate structural shape abnormalities in MCI and AD as compared with healthy controls (HC). Exploring the development to AD, we then divide the MCI participants into two subgroups based on longitudinal clinical information: (1) MCI patients who remained stable; (2) MCI patients who converted to AD over time. We focus on seven structures (amygdala, hippocampus, thalamus, caudate, putamen, globus pallidus, and lateral ventricles) in 754 MR scans (210 HC, 369 MCI of which 151 converted to AD over time, and 175 AD). The hippocampus and amygdala were further subsegmented based on high field 0.8 mm isotropic 7.0T scans for finer exploration. For MCI and AD, prominent ventricular expansions were detected and we found that these patients had strongest hippocampal atrophy occurring at CA1 and strongest amygdala atrophy at the basolateral complex. Mild atrophy in basal ganglia structures was also detected in MCI and AD. Stronger atrophy in the amygdala and hippocampus, and greater expansion in ventricles was observed in MCI converters, relative to those MCI who remained stable. Furthermore, we performed principal component analysis on a linear shape space of each structure. A subsequent linear discriminant analysis on the principal component values of hippocampus, amygdala, and ventricle leads to correct classification of 88% HC subjects and 86% AD subjects. (C) 2014 Wiley Periodicals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据